It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BFRI’s FA Score shows that 1 FA rating(s) are green whileHNSPF’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BFRI’s TA Score shows that 6 TA indicator(s) are bullish while HNSPF’s TA Score has 1 bullish TA indicator(s).
BFRI (@Pharmaceuticals: Other) experienced а -18.30% price change this week, while HNSPF (@Pharmaceuticals: Other) price change was +139.36% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.75%. For the same industry, the average monthly price growth was +1.64%, and the average quarterly price growth was -9.20%.
BFRI is expected to report earnings on Aug 11, 2023.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
BFRI | HNSPF | BFRI / HNSPF | |
Capitalization | 9.77M | 9.59B | 0% |
EBITDA | -18.45M | 3.62B | -1% |
Gain YTD | -64.108 | 145.902 | -44% |
P/E Ratio | N/A | 30.21 | - |
Revenue | 34.1M | 9.97B | 0% |
Total Cash | 1.42M | 20.9B | 0% |
Total Debt | 5.4M | 4.13B | 0% |
BFRI | HNSPF | |
---|---|---|
RSI ODDS (%) | N/A | N/A |
Stochastic ODDS (%) | 2 days ago90% | N/A |
Momentum ODDS (%) | 2 days ago90% | N/A |
MACD ODDS (%) | 2 days ago83% | 1 day ago90% |
TrendWeek ODDS (%) | 2 days ago90% | 1 day ago7% |
TrendMonth ODDS (%) | 2 days ago76% | 1 day ago4% |
Advances ODDS (%) | 9 days ago78% | N/A |
Declines ODDS (%) | 2 days ago90% | N/A |
BollingerBands ODDS (%) | 2 days ago90% | N/A |
Aroon ODDS (%) | 2 days ago84% | N/A |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
GSVSX | 16.31 | N/A | N/A |
Goldman Sachs Large Cap Value Svc | |||
NUIAX | 28.74 | -0.06 | -0.21% |
Nuveen International Dividend Growth A | |||
FTSAX | 39.43 | -0.53 | -1.33% |
FullerThaler Behvrl S-M Cor Eq A | |||
PSPIX | 29.32 | -0.42 | -1.41% |
Principal SmallCap S&P 600 Index R6 | |||
JSVAX | 28.34 | -0.47 | -1.63% |
Janus Henderson Contrarian T |
A.I.dvisor tells us that BFRI and ACET have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BFRI and ACET's prices will move in lockstep.
Ticker / NAME | Correlation To BFRI | 1D Price Change % | ||
---|---|---|---|---|
BFRI | 100% | -4.40% | ||
ACET - BFRI | 25% Poorly correlated | -0.75% | ||
DVAX - BFRI | 23% Poorly correlated | +0.39% | ||
HCM - BFRI | 23% Poorly correlated | -0.27% | ||
LNTH - BFRI | 23% Poorly correlated | -0.88% | ||
EVO - BFRI | 23% Poorly correlated | +2.36% | ||
More |